AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03564418 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-Guided Thermocoagulation of Lumbar facet joints
Description: Prone position: Thanks to a high-resolution ultrasound and a 5 MHz curved probe, we will use the ultrasound technique described by Greher et al to reach the target points.~Then, in order to check the correct positioning of the needles, we will inject 1 ml of a solution of contrast medium (omnipaque® 300 mg / ml of Iohexol) to observe them using the standard Fluoroscopic method. Wrongly positioned needles will be correctly repositioned and these patients will be excluded from ODI and VAS scale statistics.~To ensure the effectiveness of the injury by thermocoagulation, sensory electrical stimulation is performed to confirm that the needle is close to the posterior ramus (50Hz, 0-3 volts) and another electrical stimulation is performed to confirm that there is no motor stimulation (2Hz, 0-3 volts). After injecting 1 ml of 2% linisol® through the needle, denervation of the facet will be performed with an electrode at 68 ° C for 90 seconds.
Study NCT03564418 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fluoroscopy-Guided Thermocoagulation of Lumbar facet joints
Description: Prone position: We will use the standard fluoroscopic method to reach the target points. (maximum three levels, same side). Then, in order to check the correct positioning of the needles, we will inject 1 ml of a solution of contrast medium (omnipaque® 300 mg / ml of Iohexol). The correct location being the superolateral edge of the lateral facet and the diffusion of the contrast material at the level of the medial branch observed thanks to an anteroposterior radioscopic view. Then the location of the needles is confirmed by a lateral radioscopic view.~To ensure the effectiveness of the injury by thermocoagulation, sensory electrical stimulation is performed to confirm that it is close to the posterior ramus (50Hz, 0-3 volts) and another electrical stimulation is performed to confirm that there is no motor stimulation (2Hz, 0-3 volts). After injecting 1 ml of 2% linisol® through the needle, denervation of the facet will be performed with an electrode at 68 ° C for 90 seconds.
Study NCT04404946 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: phenylephrine infusion
Description: in parturients allocated to the phenylephrine group, a phenylephrine infusion will be started as soon as spinal anesthesia is initiated
Study NCT04404946 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: norepinephrine infusion
Description: in parturients allocated to the norepinephrine group, a norepinephrine infusion will be started as soon as spinal anesthesia is initiated
Study NCT04404946 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo infusion
Description: in parturients allocated to the placebo group, a normal saline infusion will be started as soon as spinal anesthesia is initiated
Study NCT00523536 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigator - Nurse Team Intervention
Description: The patient navigator-nurse disease management intervention for treating hypertension and its associated cardiovascular risk factors will use information obtained in earlier phases of the LUCHAR grant: i.e., algorithms, risk factor profiles, and qualitative data from focus groups and interviews. The study will test the effect of this intervention on blood pressure control and utilization of hospital services in adult patients with hypertension.
Study NCT02054130 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received placebo matched to MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.
Study NCT00989612 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza investigational vaccine GSK2340274A
Description: Two intramuscular injections on Day 0 and Day 21, respectively
Study NCT03487328 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sacrospinous-Sacrotuberous fixation
Description: Sacrospinous-Sacrotuberous fixation
Study NCT02054130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI9929 70 mg
Description: Participants received 70 milligram (mg) of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.
Study NCT02054130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI9929 210 mg
Description: Participants received 210 mg of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.
Study NCT04180228 — intervention group
Intervention type: OTHER
Intervention: self-administred questionnaire
Description: On the occasion of a follow-up consultation with referent pediatrician, a self-administred questionnaire is distributed. It will take around ten minutes to the patient and her parents for completing the questionnaire. Questionnaire is anonymous. Participation is free and informed by an information notice. There is a list of items to complete by the patient and her parents. Most of questions are closed-ended. Clinical data are reported : age, level of education, principal disease (SLE or Juvenile arthritis), received treatments. In the questionnaire, it is asked if the patient is vaccinated or not for HPV, and reasons for it.
Study NCT03437369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine Oral Tablet
Description: The target dose is 10 to 15 mg / day, administered orally in two doses
Study NCT03437369 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care treatment
Description: The study drug will be compared with the standard of Care treatment
Study NCT02501902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib oral dosing on Days 1 to 21 of each 28-day cycle.
Study NCT03346187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Comparator(Atorvastatin Calcium Trihydrate+Fenofibrate)
Description: Lipitor(Atorvastatin Calcium Trihydrate 20mg/tablet) + Lipidil supra(Fenofibrate 160mg/tablet)
Study NCT03346187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug(CKD-337)
Description: CKD-337(Atorvastatin calcium trihydrate 20mg+choline fenofibrate 178.8mg/capsule)
Study NCT02869165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen topical cream
Description: Comparison of the bacterial communities in the vagina and urine of postmenopausal women who use Premarin vaginal cream versus apricot kernel oil and to themselves before and after use.
Study NCT02869165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apricot kernel oil
Description: Comparison of the bacterial communities in the vagina and urine of postmenopausal women who use Premarin vaginal cream versus apricot kernel oil and to themselves before and after use.
Study NCT03618667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC1118
Description: GC1118 (4mg/kg) will be administered by IV infusion once per week for 4 weeks(28-day cycles) up to 6 cycles, or till progression or uncontrolled toxicity.
Study NCT03673540 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT+ application
Description: Smartphone application that comprises electronic self-monitoring of food intake, eating disorder behaviors, and mood and ecological momentary interventions
Study NCT03688919 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Regulation Intervention
Description: The intervention targets Executive Functioning (EF), Emotion Regulation (ER) and Future Orientation (FO). The intervention will occur through home practice and text based reminders and mobile apps to practice techniques. For EF, youth will use the NBack intervention, a computer-based working memory training game. For ER, participants will engage in relaxation and biofeedback activities by completing activities (e.g., modulating breathing to keep heart rate) while wearing sensors. For FO, participants will envision and describe future events they are looking forward to, using concrete, vivid descriptive language. These descriptions will be audio recorded so that the participant can play back the cues at home at specified times of day (e.g., 7am and 3:30PM).
Study NCT02671006 — intervention group
Intervention type: OTHER
Intervention: Basophil patterns
Description: The Basophil patterns (CUBIC) will be compared between patients with urticaria and controls without Chronic Urticaria.
Study NCT04572646 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: NRT proposition and exhaled CO measurement
Description: Nicotine replacement therapy is proposed to every patient included in the study.~Whether the patient accepts the therapy or not, exhaled carbon monoxide is measured at the preoperative consultation (about 15 days before surgery) and the day of surgery by a nurse. These two measures are compared to assess efficacy of nicotine replacement therapy.
Study NCT02797756 — intervention group
Intervention type: PROCEDURE
Intervention: Esophago-gastro-duodenoscopy (EGD) with biopsy
Study NCT02797756 — intervention group
Intervention type: PROCEDURE
Intervention: Esophageal Impedance Monitoring (EIM)
Study NCT00118274 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: incomplete Freund's adjuvant
Description: Given intradermally and subcutaneously
Study NCT00118274 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: melanoma helper peptide vaccine
Description: Given intradermally and subcutaneously
Study NCT00118274 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: multi-epitope melanoma peptide vaccine
Description: Given intradermally and subcutaneously
Study NCT00118274 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tetanus toxoid helper peptide
Description: Given intradermally and subcutaneously
Study NCT00118274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT01029912 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical stimulator
Description: 6-week intervention~15 minutes of therapist-guided stimulated ankle exercise + 30 minutes of physical therapy in the laboratory twice a week.~Self-administered active repetitive ankle dorsiflexion exercise performed twice a day, 6 days a week at home using the device.
Study NCT01029912 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electrical stimulator
Description: 6-week intervention~15 minutes of therapist-guided stimulated ankle exercise + 30 minutes of physical therapy in the laboratory twice a week.~Self-administered active repetitive ankle dorsiflexion exercise performed twice a day, 6 days a week at home using the device.
Study NCT01065025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4SC-205
Description: Repeated ascending oral doses of 4SC-205.
Study NCT04588636 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: behavioral and self-care therapy
Description: It is based on the premise that cognition, the process of acquiring knowledge and forming beliefs, is a primary determinant of mood and behavior. The therapy uses behavioral and self-care techniques to identify, correct and prevent behaviors or situations capable of altering the subject's state
Study NCT04588636 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: behavioral and self-care therapy
Description: It is based on the premise that cognition, the process of acquiring knowledge and forming beliefs, is a primary determinant of mood and behavior. The therapy uses behavioral and self-care techniques to identify, correct and prevent behaviors or situations capable of altering the subject's state
Study NCT04588636 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rigid occlusal splint (ROS)
Description: Occlusal splint formed in a vacuum from rigid individual sheets of 2 mm thick polyethylene terephthalate (Biolon, Dreve, Unna, Germany).
Study NCT04588636 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: soft occlusal splint (SOS)
Description: Occlusal splint formed in a vacuum from 3 mm thick individual soft sheets of ethyl vinyl acetate (Drufosoft, Dreve, Unna, Germany).
Study NCT04588636 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: non-occlusive splint (NOS)
Description: non-occlusive splint formed under vacuum from individual sheets of rigid polyethylene terephthalate 2 mm thick (Biolon, Dreve, Unna, Germany), from which the occlusal surfaces were cut and incisal edges, allowing the usual occlusal contact of each subject.
Study NCT01285024 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vitagel
Description: Two 4.5mL Vitagel Surgical Hemostat Kits, used just prior to closing the capsule.
Study NCT04365426 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical stimulus
Description: Electrical dynamometer to measure mechanical pressure
Study NCT02501902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: Nab-paclitaxel IV dosing on Days -2, 6, and 13 of Cycle 1, and on Days 1, 8, and 15 of subsequent cycles.
Study NCT02518776 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Neuropsychological tests
Description: Neuropsychological tests
Study NCT04060810 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MR CSF flowmetry
Description: MR flowmetry in grey zone hydro cephalic patients followed by ventriculoperitoneal shunt
Study NCT03027388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LB-100
Description: LB-100 will be infused over 2 hours via intravenous (IV) infusion 2 to 4 hours before surgery. The dose established from a Phase I study will be 2.33 mg/m\^2.
Study NCT04169685 — intervention group
Intervention type: PROCEDURE
Intervention: bronchoscopy
Description: during flexible bronchoscopy
Study NCT03515018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxyurea
Description: pulse therapy
Study NCT03515018 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib
Description: 400mg qd PO per day
Study NCT02760160 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Reconstituted grape powder
Description: To prevent UV-induced skin cancers. Each subject's will have one arm exposed to 6 separate doses of UV (J/m2) \[114, 217, 343, 500, 619, 848\].
Study NCT00734812 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic supracervical hysterectomy
Description: Patients will be randomized to LSH (retaining the cervix) and TLH (cervix removal)
Study NCT00916097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOCETAXEL(XRP6976)
Description: docetaxel 75mg/m2 by intravenous infusion over 60 minutes on Day 1 of a 3-week cycle
Study NCT04920019 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic continuous epidural analgesia
Description: Continuous epidural catheter (Portex ™, Epidural Minipack , Smiths Medical), infused with 0.0625% bupivacaine (Marcaine™, Aspen Holdings) with morphine (morphine M\&H™) 0.02 mg/ml 5 ml/h postoperative until POD3 morning Connected with The Sapphire ™ Infusion System Patient-Controlled-Analgesia (PCA) pump(fentanyl (fentanyl-Hameln™, Siam Bioscience): intravenous bolus mode only 15 ug/bolus, lockout interval 5 minutes, 4-hour limit 200 ug)~Postoprative analgesia: intravenous paracetamol (infulgan ™, Yuria-Pharm), tablet paracetamol (SaRa ™), Parecoxib (Dynastat ™, Pfizer), Etoricoxib (Arcoxia ™, MSD)
Study NCT04920019 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic continuous epidural analgesia
Description: Continuous epidural catheter (Portex ™, Epidural Minipack , Smiths Medical), infused with 0.0625% bupivacaine (Marcaine™, Aspen Holdings) with morphine (morphine M\&H™) 0.02 mg/ml 5 ml/h postoperative until POD3 morning Connected with The Sapphire ™ Infusion System Patient-Controlled-Analgesia (PCA) pump(fentanyl (fentanyl-Hameln™, Siam Bioscience): intravenous bolus mode only 15 ug/bolus, lockout interval 5 minutes, 4-hour limit 200 ug)~Postoprative analgesia: intravenous paracetamol (infulgan ™, Yuria-Pharm), tablet paracetamol (SaRa ™), Parecoxib (Dynastat ™, Pfizer), Etoricoxib (Arcoxia ™, MSD)
Study NCT01753505 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 64-slice Multidetector coronary CT angiography
Study NCT02367937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRC-4016 (icosabutate)
Description: Midazolam, omeprazole, flurbiprofen and simvastatin interaction with PRC-4016. Detailed description under Study description
Study NCT00508716 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Literacy-Tailored Education
Description: Intervention group receives a visit from a nurse educator who, using the teach back method of educating patients, provides counseling on their disease methods of controlling their disease. A video is also viewed to reinforce the materials.
Study NCT01858389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacomitinib
Description: Dacomitinib 45 mg every 12 hours Days 1-4 of the first week, and then 60 mg every 12 hours Days 1-4 of each 2-week cycle thereafter. The dose of dacomitinib for patients in Cohort A may be further escalated in increments of 15 mg.
Study NCT01858389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacomitinib
Description: Dacomitinib 45 mg every 12 hours Days 1-4 of the first week, and then 60 mg every 12 hours Days 1-4 of each 2-week cycle thereafter.
Study NCT01269463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate Hydrochloride Extended Release Capsule
Description: An optimized dose of Methylphenidate Hydrochloride Extended Release Capsules 15, 20, 30 or 40 mg to be dosed once daily
Study NCT01269463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsule without active drug
Study NCT00750815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Enroll patients into 4 different dose levels. The dose of Cyclophosphamide they receive will depend on how many patients have been treated.
Study NCT00750815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib; Pegylated Liposomal Doxorubicin; Dexamethasone (VDD)
Description: Patients will receive Bortezomib, Pegylated Liposomal Doxorubicin and Dexamethasone at standard doses.
Study NCT01125267 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multifamily group-adherence
Description: multifamily groups held twice a month for one year focused on improving medication adherence using techniques derived from the Theory of Planned Behavior
Study NCT00734812 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total laparoscopic hysterectomy
Description: Patients will be randomized to either removal or retention of cervix
Study NCT04745078 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Caboxy30
Description: carboxy30 to periorbital dark halos
Study NCT04745078 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Caboxy60
Description: carboxy60 to periorbital dark halos
Study NCT04146519 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous mesenchymal stem cells
Description: Autologous mesenchymal stem cells
Study NCT04146519 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution
Study NCT04365426 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thermal (cold) stimulus
Description: Water cold bath
Study NCT04365426 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral contraceptive (OC)
Description: Oral contraceptive (OC)
Study NCT04365426 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No oral contraceptive (No OC)
Description: No oral contraceptive (No OC)
Study NCT03771040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Masitinib
Study NCT03771040 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04463940 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT02153437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-919373
Study NCT02153437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sotalol
Study NCT02153437 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for BMS-919373
Study NCT00570323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arimidex
Description: Aromatase inhibitors
Study NCT00570323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Faslodex
Description: Hormone Receptor
Study NCT02056028 — intervention group
Intervention type: PROCEDURE
Intervention: Hepatic resection
Study NCT04406402 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acute dietary protocols and lifestyle modification
Description: The investigators tested the effects on serum Arg and ADMA of a) a single load of ingested dextrose, protein, fat or alcohol, each consumed within 10 minutes; b) a single episode of physical exercise; c) a 12 weeks lifestyle modification program comprised of a standard dietary and physical activity counseling in obese or T2DM subjects on circulating Arg and ADMA (n=43).
Study NCT05357768 — intervention group
Intervention type: OTHER
Intervention: data collection and analysis on Formalin-fixed paraffin embedded tissue and/or frozen tumoral tissue
Description: Formalin-fixed paraffin embedded tissue and/or frozen tumoral tissue of cases negative for all Ewing's sarcoma molecular fusions, will be analyzed for the presence of CIC-DUX4 / BCOR-CCNB3 translocations fusion at each Institution.~Treatment, outcome, and prognostic factors will be related with the molecular re-classification.
Study NCT01905189 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resynchronization therapy of right ventricle
Description: Right atrio-ventricular resynchronization therapy combined with right intra-ventricular resynchronization therapy